Germany’s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of its blockbuster Covid vaccine drop.
The biotech company plans to stop operating at three manufacturing sites in Germany by the end of 2027, it said, while a site in Singapore would cease work in the first quarter of next year.
Sites of former competitor CureVac — which BioNTech acquired last year — would also stop making vaccines, BioNTech added.
The moves will save up to 500 million euros ($585 million) in costs annually by 2029, BioNTech said, adding that about 1,860 jobs would be affected.
“BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected,” the company said.
“For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale,” it added.
Reporting earnings for the first quarter, BioNTech said sales had fallen 35 percent to 118.1 million euros, hit by lower sales of its Covid vaccines.
BioNTech’s loss widened to 531.9 million euros from 415.8 million euros for the same period last year.
“In 2026, BioNTech anticipates lower Covid-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets,” BioNTech said.
BioNTech is best-known for the mRNA-based Comirnarty coronavirus vaccine developed with US pharmaceutical giant Pfizer — the first Covid vaccine to receive approval in the West and the first mRNA vaccine to receive approval for widespread use.
The company has in recent times made a pivot towards developing cancer treatments based on the gene technology.
In March BioNTech said married couple Ugur Sahin and Ozlem Tureci, who serve as CEO and chief medical officer, would step down at the end of their terms in 2026 to start a new business.
Add Comment